Showing results (41-50 of 1,066) with videos related to
Sort By:
Pageof 107
Pharmacology & Toxicology|April 1, 1987
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatmentK Brøsen, L F Gram, T Haghfelt, et al.European Journal of Clinical Pharmacology|January 1, 1988
Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology departmentF Davidsen, T Haghfelt, L F Gram, et al.Clinical Pharmacology and Therapeutics|January 1, 1991
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramineE Skjelbo, K Brøsen, J Hallas, et al.The Clinical Journal of Pain|June 1, 1992
Plasma beta-endorphin is not affected by treatment with imipramine or paroxetine in patients with diabetic neuropathy symptomsS H Sindrup, F W Bach, L F GramEuropean Journal of Clinical Pharmacology|January 1, 1986
Steady-state levels of imipramine and its metabolites: significance of dose-dependent kineticsK Brøsen, L F Gram, R Klysner, et al.Clinical Pharmacokinetics|July 1, 1980
Plasma concentration and clinical effect in imipramine treatment of childhood enuresisO S Jorgensen, M Lober, J Christiansen, et al.British Journal of Clinical Pharmacology|April 1, 1996
Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994D Gaist, J Hallas, N C Hansen, et al.Scandinavian Journal of Primary Health Care|December 1, 1995
Antidepressant treatment in general practice--an interview studyJ U Rosholm, L F Gram, N Damsbo, et al.Therapeutic Drug Monitoring|September 1, 1989
Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotypeL F Gram, K Brøsen, P Kragh-Sørensen, et al.European Journal of Clinical Pharmacology|January 1, 1984
D-propoxyphene kinetics in man: significance of a deep third compartmentL F Gram, K Schmidt, F N Christensen, et al.Pageof 107